Filing Manager
CITADEL ADVISORS LLC
Reporting Manager
Kenneth Griffin
Symbol
BBOT
Shares outstanding
79,316,938 shares
Disclosed Ownership
2,538,142 shares
Ownership
3.2%
Form type
SCHEDULE 13G/A
Filing time
14 Nov 2025, 16:09:22 UTC
Date of event
30 Sep 2025

Sponsored

Quoteable Key Fact

"CITADEL ADVISORS LLC disclosed 3.2% ownership in BridgeBio Oncology Therapeutics, Inc. Class A ordinary share, par value $0.0001 per share (the "Shares") (BBOT) on 30 Sep 2025."

Quick Takeaways

  • CITADEL ADVISORS LLC filed SCHEDULE 13G/A for BridgeBio Oncology Therapeutics, Inc. Class A ordinary share, par value $0.0001 per share (the "Shares") (BBOT).
  • Disclosed ownership: 3.2%.
  • Date of event: 30 Sep 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 14 Nov 2025, 16:09.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (7)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Citadel Advisors LLC 3.2% 2,528,762 0 2,528,762 /s/ Seth Levy Seth Levy, Authorized Signatory
Citadel Advisors Holdings LP 3.2% 2,528,762 0 2,528,762 /s/ Seth Levy Seth Levy, Authorized Signatory
Citadel GP LLC 3.2% 2,528,762 0 2,528,762 /s/ Seth Levy Seth Levy, Authorized Signatory
Citadel Securities LLC 0% 9,380 0 9,380 /s/ Seth Levy Seth Levy, Authorized Signatory
Citadel Securities Group LP 0% 9,380 0 9,380 /s/ Seth Levy Seth Levy, Authorized Signatory
Citadel Securities GP LLC 0% 9,380 0 9,380 /s/ Seth Levy Seth Levy, Authorized Signatory
Kenneth Griffin 3.2% 2,538,142 0 2,538,142 /s/ Seth Levy Seth Levy, attorney-in-fact*